Uncontrolled Asthma Clinical Trial
Official title:
Evaluation of a Community Pharmacist Managed Asthma Consultation Service
Asthma is one of the most common chronic health conditions, affecting 900,000 Ontarians, 2.4
million Canadians and over 300 million people worldwide. Unlike most other chronic diseases,
asthma affects a significant proportion of children - an estimated 21% in Ontario. Asthma is
also the leading cause of hospitalization for children in Canada and is a significant cause
of school and work absenteeism. Though asthma is generally considered a chronic disease, it
can be fatal in some instances - in 2009, an estimated 91 Ontarians died of this condition.
Effective management of asthma can prevent exacerbation and more severe negative health
consequences. In fact, estimates show that over 80% of the asthma-related deaths could be
prevented through proper education. However, evidence also shows that over 55% of patients
with moderate to severe asthma do not have their asthma symptoms under control, despite
regular doctor visits. Less than a third (31%) of asthma patients report receiving an asthma
action plan from their physicians, although such plans are associated with fewer ER visits,
lower hospitalization rates and improved lung function. Hence, there is a clear opportunity
to improve the management of asthma and reduce the incidence of related complications.
Given the scientific evidence of pharmacists effect on asthma management there is a strong
rationale for introducing an asthma-specific pharmacist-led intervention for Ontarians
suffering from this chronic disease. However, the implementation of such a program should be
preceded by a pilot test to ensure that the program parameters are optimized to drive
improved patient outcomes and maximum quality of service. The primary goals of this research
project are to examine the impact of a pharmacist led asthma management intervention on
patient health outcomes and to determine the optimum program structure to ensure quality of
service delivery.
This study employs a mixed-methods study design. Investigators will begin with a cluster
randomized controlled trial and end with exit interviews.This study will consist of a
prospective, randomized controlled trial conducted in the community setting. A total of 12
pharmacies across the Greater Toronto Region will be recruited for this study. Each of these
pharmacies will be randomly assigned in a 1:1 ratio to either the intervention group or the
control group. All data will be analyzed using statistical software. Significance level will
be set at 0.05. Pharmacy level descriptive characteristics, including mean and standard
deviation for the number of patients will be reported. There is a low perceived risk for this
study; however, the investigators will take every precaution to ensure this study is
conducted in an ethical manner, including protecting patient confidentiality and anonymity.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02194699 -
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
|
Phase 3 | |
| Recruiting |
NCT06029595 -
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT03978936 -
Medication Adherence With Telehealthcare Medication Therapy Management
|
N/A | |
| Completed |
NCT02161757 -
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
|
Phase 3 | |
| Completed |
NCT02906761 -
Aspirin for Uncontrolled Asthma
|
Phase 3 | |
| Completed |
NCT04865575 -
Systems Pharmacology Approach to Uncontrolled Pediatric Asthma
|